RankingsPricing
  1. US-listed companies
  2. LIGAND PHARMACEUTICALS INC
  3. Financials
  4. Cash from investing

LIGAND PHARMACEUTICALS INC【LGND】

Market cap
$4B
P/E ratio
SummaryFinancials
Period EndCash from investing (Million USD)YoY (%)
Dec 31, 2024-144+1129.79%
Dec 31, 2023-12-107.14%
Dec 31, 2022164+436.07%
Dec 31, 202131-86.82%
Dec 31, 2020232-50.39%
Dec 31, 2019467-210.31%
Dec 31, 2018-423+402.83%
Dec 31, 2017-84-41.21%
Dec 31, 2016-143+26.87%
Dec 31, 2015-113+5467.93%
Dec 31, 2014-2-59.25%
Dec 31, 2013-5-493.82%
Dec 31, 20121-105.03%
Dec 31, 2011-25

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating income Operating expenses Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSAdjusted EPSDividend payout ratio (%)Dividend per shareAdjusted DPSEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)